Literature DB >> 12447099

COX-2 inhibitors and their role in gynecology.

Ellen C Hayes1, John A Rock.   

Abstract

UNLABELLED: This review summarizes current knowledge about the roles of cyclooxygenases and prostaglandins in reproductive medicine. With the development of COX-2 specific inhibitors, new therapeutic options are available to obstetricians and gynecologists, offering better-tolerated alternatives to conventional NSAIDs. The analgesic effectiveness of COX-2 specific inhibitors is well established, and they are already in use in a range of painful conditions. Both celecoxib and valdecoxib are indicated for the treatment of primary dysmenorrhea, and may be effective in postoperative pain, including hysterectomy, and pain associated with endometriosis. There is also speculation that COX-2 specific inhibitors may be effective tocolytic agents without the risks to the fetus seen with conventional NSAIDs. The role of COX-2 in oncogenesis is also under investigation, and COX-2 specific inhibitors may eventually be used in the prevention and treatment of gynecologic malignancies. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians Learning
Objectives: After completion of this article, the reader will be able to describe the two types of cylooxygenase enzymes (COX), to list the effects and side effects of NSAIDs and COX-2 medications, and to outline the various changes in COX expression during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447099     DOI: 10.1097/00006254-200211000-00023

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  7 in total

1.  Stress and dysmenorrhoea: a population based prospective study.

Authors:  L Wang; X Wang; W Wang; C Chen; A G Ronnennberg; W Guang; A Huang; Z Fang; T Zang; L Wang; X Xu
Journal:  Occup Environ Med       Date:  2004-12       Impact factor: 4.402

Review 2.  Endometriosis.

Authors:  Serdar E Bulun; Bahar D Yilmaz; Christia Sison; Kaoru Miyazaki; Lia Bernardi; Shimeng Liu; Amanda Kohlmeier; Ping Yin; Magdy Milad; JianJun Wei
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

Review 3.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.

Authors:  J Julie Kim; Takeshi Kurita; Serdar E Bulun
Journal:  Endocr Rev       Date:  2013-01-09       Impact factor: 19.871

4.  Morinda citrifolia (Noni) as an Anti-Inflammatory Treatment in Women with Primary Dysmenorrhoea: A Randomised Double-Blind Placebo-Controlled Trial.

Authors:  H M Fletcher; J Dawkins; C Rattray; G Wharfe; M Reid; G Gordon-Strachan
Journal:  Obstet Gynecol Int       Date:  2013-01-29

5.  Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part II: Identification of enzyme inhibitors from Prasaplai, a Thai traditional medicine.

Authors:  Birgit Waltenberger; Daniela Schuster; Sompol Paramapojn; Wandee Gritsanapan; Gerhard Wolber; Judith M Rollinger; Hermann Stuppner
Journal:  Phytomedicine       Date:  2010-09-20       Impact factor: 5.340

6.  Development of pro-apoptotic peptides as potential therapy for peritoneal endometriosis.

Authors:  K Sugihara; Y Kobayashi; A Suzuki; N Tamura; K Motamedchaboki; C-T Huang; T O Akama; J Pecotte; P Frost; C Bauer; J B Jimenez; J Nakayama; D Aoki; M N Fukuda
Journal:  Nat Commun       Date:  2014-07-22       Impact factor: 14.919

Review 7.  Medical treatments for endometriosis-associated pelvic pain.

Authors:  Gabriella Zito; Stefania Luppi; Elena Giolo; Monica Martinelli; Irene Venturin; Giovanni Di Lorenzo; Giuseppe Ricci
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.